Earnings Roundup: Washington Post, AH Belo
Earnings roundup: Washington Post profit rises on cable TV, ed units; AH Belo cuts costs
02:18PM 10/30/09
MoneyGram Narrows 3Q Loss, But Misses Street View
MoneyGram narrows 3rd-quarter loss as sales rise, but misses Street view; shares fall
12:48PM 10/30/09
The Increasingly Speculative Templetons (RealMoney.com $)
Buying NYSE stocks under $3 has been lucrative, but the pickings are smaller and riskier.
03:45PM 09/02/09
Mad Money Post Game: Obama Winners
Jim Cramer argues that Western Union can surge to $30 and believes that the healthcare stock fears are overblown.
02:15PM 07/23/09
Cramer's 'Mad Money' Recap: On the Road to Recovery (Update 3)
Cramer says the plague has run its course and many stocks are a lot healthier than investors think. Click for news from Jim Cramer.
06:42PM 07/22/09
Cramer: Visa - Faster Growth than Tech
By Jim Cramer | By Stephanie Link
Jim Cramer and Stephanie Link, Director of Research for Cramer's Action Alerts Plus Portfolio like Visa as a trade off of paper to plastic. Real Money TV viewers get Cramer's videos first and commercial free!
08:59AM 04/22/09
Wall Street Confidential: April 22
By Stephanie Link | By Jim Cramer
Jim Cramer discusses the market.
05:59AM 04/22/09
Cramer: Visa - Faster Growth than Tech
By Jim Cramer | By Stephanie Link
Jim Cramer and Stephanie Link, Director of Research for Cramer's Action Alerts Plus Portfolio like Visa as a trade off of paper to plastic. Real Money TV viewers get Cramer's videos first and commercial free!
11:26AM 04/20/09
Fitch Affirms MoneyGram's Junk Rating
Fitch affirms junk status rating on MoneyGram International
12:57PM 03/30/09
Positive Data Provide Spark to New Name (Biotech Select $)
Establishing a long position in this health care company, whose cancer drug should get approved before the end of the year. Also, an in-depth analysis of a new stock to watch.
08:45AM 02/25/09
Here's what some of our market pros are saying and playing.
04:33PM 02/04/09
Allos: Blood Cancer Data Promising
Allos Therapeutics says patients with peripheral T-cell lymphoma responded to treatment with the company's experimental drug pralatrexate for more than nine months.
03:15PM 02/04/09
Insider Buys $3.2 Million of Calpine
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:12AM 12/31/08



Connect with TheStreet